Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Deciphering the genomic landscape of renal cell carcinoma brain metastases.

Betul Gok Yavuz, Peng Li, Jose A. Ovando-Ricardez et al. Jun 01, 2026 pp. 4524-4524 10.1200/jco.2026.44.16_suppl.4524

4524 Background: Brain metastases from renal cell carcinoma (RCC) remain a major cause of morbidity and mortality, yet the...

Adjuvant platinum-based chemotherapy vs observation after resection of stage I–IIa (N0) NSCLC: A real-world propensity-matched analysis from TriNetX.

Mohammed Abdalkarim, Mamtha Balla, Thaer Alhroob et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20059

e20059 Background: Lung cancer remains the leading cause of cancer-related mortality worldwide, accounting for approximate...

Efficacy of chemotherapy with salvage surgery for locoregionally recurrent nasopharyngeal carcinoma: A multicenter cohort study.

Wei Jiang, Bing Liu, Zhenya Li et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18073

e18073 Background: The role of chemotherapy combined with salvage surgery for locoregionally recurrent nasopharyngeal carc...

Cancer disparities in Latinx communities of Western North Carolina and Appalachia: A scoping review of barriers and pathways to equity.

Eduardo Reyes, Jonathan Hong Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13754

e13754 Background: Appalachia experiences some of the highest cancer incidence and mortality rates in the United States. I...

Chemoimmunotherapy for large cell neuroendocrine carcinoma (LCNEC) of the lung: A multi-institutional prospective study (NEJ044).

Suguru Matsuda, Tetsuhiko Asao, Takehito Shukuya et al. Jun 01, 2026 pp. 8078-8078 10.1200/jco.2026.44.16_suppl.8078

8078 Background: Large cell neuroendocrine carcinoma (LCNEC) is a rare pulmonary malignancy, comprising 1-3% of all lung c...

Pregnancy outcomes in women with myeloproliferative neoplasms: A multicenter real-world analysis.

Maryam Naser, Ruchi Desai Jun 01, 2026 pp. 6574-6574 10.1200/jco.2026.44.16_suppl.6574

6574 Background: Pregnancy in women with myeloproliferative neoplasms (MPNs) is associated with increased thrombotic and o...

A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II—ECOG-ACRIN EA2234.

Maheswari Senthil, Sung Chul Hong, Nataliya V. Uboha et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps4241

TPS4241 Background: Thirty to forty percent of patients with gastric cancer will develop peritoneal carcinomatosis (PC), t...

Decoding the pre-malignant niche in cholangiocarcinoma: A single-cell multi-omic atlas from inflammation to invasion.

Siming Kong, Rongyan Yao, Hui Bai et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22555

e22555 Background: The dismal prognosis of extrahepatic cholangiocarcinoma (eCCA) is primarily attributable to late-stage...

Multichannel deep learning network for predicting survival in stage I NSCLC patients treated with SBRT.

Kaushik Halder, Michael D. Mix, Rihan Podder et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20108

e20108 Background: This study aims to develop a deep learning network (DLN)-based model to predict overall survival (OS) b...

Cadonilimab combined with anlotinib in patients with advanced NSCLC refractory to prior systemic therapy and anti–PD-(L)1 antibodies: A phase II study.

Juncai Ye, Min Hou, Daiyuan Ma et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20507

e20507 Background: The combination of immunotherapy and antiangiogenic therapy represents a promising first-line strategy...

Phase IIa study of tosposertib, a dual TGFβRI and VEGFR2 inhibitor, in combination with pembrolizumab in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Hye Ryun Kim, Bhumsuk Keam, Sung-Bae Kim et al. Jun 01, 2026 pp. 2635-2635 10.1200/jco.2026.44.16_suppl.2635

2635 Background: Tosposertib (TU2218) is a highly potent dual inhibitor of the transforming growth factor-β type I recepto...

A prospective randomized controlled trial of FAPI PET/CT-guided radiotherapy combined with second-line standard systemic treatment and cadonilimab versus second-line standard systemic treatment alone in patients with peritoneal metastasis from colorectal cancer (TORCH-PM01).

Juefeng Wan, Weixing Dai, Zhen Zhang et al. Jun 01, 2026 pp. 3545-3545 10.1200/jco.2026.44.16_suppl.3545

3545 Background: This study evaluates the efficacy and safety of FAPI PET/CT-guided radiotherapy combined with second-line...

Delays in receipt of neoadjuvant chemotherapy in patients with localized muscle-invasive bladder cancer.

Margaux Wooster, Rohit R. Raghunathan, Jason Dennis Wright et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13538

e13538 Background: Delay in time from muscle invasive bladder cancer (MIBC) diagnosis to neoadjuvant chemotherapy (NACT) &...

A population tumor kinetics analysis for early-cycle ctDNA-guided therapy decisions in DLBCL.

Kunhee Kim, Adam C. Palmer Jun 01, 2026 pp. 3054-3054 10.1200/jco.2026.44.16_suppl.3054

3054 Background: Early circulating tumor DNA (ctDNA) kinetics may be instrumental in identifying patients with DLBCL who c...

Evaluation of serum folate receptor alpha levels in colon cancer: Association with diagnosis, clinical stage, and metastasis.

Lutfullah Zahit Koc, Sevgi Gulsen Koc, Derya Kıvrak Salim et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15052

e15052 Background: Folate and folate receptor alpha (FRα) are critical for cell proliferation and DNA synthesis. FRα is ov...

Healthcare provider perceptions and barriers to palliative care in Pakistan: A narrative synthesis.

Muhammad Kashif Amin, Amna Bint I Munir, Asma Zakir et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13640

e13640 Background: Palliative care integration in Pakistan remains limited despite a high cancer burden in this low-resour...

Multi-omic characterization of high tumor mutational burden in colorectal cancer.

R. K. Choudhary, Debapriya Mondal, Harsh Vardhan Atreya et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15724

e15724 Background: High Tumor Mutational Burden (TMB-H) is a primary biomarker for immune checkpoint inhibitor response in...

BI-1808 + pembrolizumab: Responses to a chemotherapy-free regimen in advanced ovarian cancer.

Anja Williams, Rebecca Kristeleit, Juanita Suzanne Lopez et al. Jun 01, 2026 pp. 2605-2605 10.1200/jco.2026.44.16_suppl.2605

2605 Background: Up to 80% of individuals with advanced ovarian cancer experience disease progression after standard plati...

Forecasting global disparities in cervix and corpus uteri cancers: GLOBOCAN 2022–2040 projections.

Sonia Babu, Berkha Rani, Ahmad Abed et al. Jun 01, 2026 pp. 5614-5614 10.1200/jco.2026.44.16_suppl.5614

5614 Background: Uterine cancers, including cervix uteri (C53) and corpus uteri (C54), are a major burden on global health...

Early treatment failure despite first-line immunotherapy in real-world MSI-H/dMMR gastroesophageal cancer.

Shannon L. Rhodes, Elizabeth Won, Antreas Hindoyan et al. Jun 01, 2026 pp. 4029-4029 10.1200/jco.2026.44.16_suppl.4029

4029 Background: Clinical trials of first-line (1L) immunotherapy (IO) in gastroesophageal cancer (GEC) demonstrate greate...

Trastuzumab deruxtecan in patients with HER2-low recurrent/metastatic salivary gland carcinoma: Results from the phase II MYTHOS trial.

Ichiro Kinoshita, Satoshi Kano, Yoshitaka Honma et al. Jun 01, 2026 pp. 6011-6011 10.1200/jco.2026.44.16_suppl.6011

6011 Background: Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody–drug conjugate with established efficacy acros...

Risk factors and long-term prognostic impact of trastuzumab deruxtecan-related interstitial lung disease in metastatic breast cancer.

Takayuki Kobayashi, Meiko Nishimura, Jun Masuda et al. Jun 01, 2026 pp. 1043-1043 10.1200/jco.2026.44.16_suppl.1043

1043 Background: Trastuzumab deruxtecan (T-DXd) has demonstrated substantial efficacy in HER2-positive and HER2-low metast...

Trends and disparities in cancer mortality among adults with psychoactive drug use disorders in United States, 1999–2023.

Kaneez Fatima, Nayanika Chowdary Tummala, Vishan Das et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15132

e15132 Background: Psychoactive drug use is a growing public health concern and is linked to increased cancer risk through...

Trends in early-onset colorectal cancer: A 20-year epidemiological study at a referral center in northeastern Mexico.

Hector Alejandro Rodriguez-Calvillo, Omar A. Zayas, David Hernandez et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15695

e15695 Background: Colorectal cancer (CRC) ranks as the third most common malignancy and the second leading cause of cance...

Histopathological patterns of breast cancer at diagnosis among patients in the Federal Capital Territory, Abuja: Findings from the Network for Oncology Research in Sub-Saharan Africa (NORA) study.

Ayobami Godswill Ademola, Chigbo Godswill Chisom, Yusuff Akinkunmi Olasunkanmi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24095

e24095 Background: Breast cancer is the most diagnosed malignancy among women in Nigeria. Histopathological characteristic...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page